Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Change in Cash (2016 - 2025)

Historic Change in Cash for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to -$25.0 million.

  • Arrowhead Pharmaceuticals' Change in Cash rose 4867.22% to -$25.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $148.0 million, marking a year-over-year increase of 186230.8%. This contributed to the annual value of $124.3 million for FY2025, which is 110188.66% up from last year.
  • According to the latest figures from Q4 2025, Arrowhead Pharmaceuticals' Change in Cash is -$25.0 million, which was up 4867.22% from $96.8 million recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Change in Cash ranged from a high of $232.5 million in Q1 2021 and a low of -$141.5 million during Q3 2021
  • Over the past 5 years, Arrowhead Pharmaceuticals' median Change in Cash value was -$27.3 million (recorded in 2023), while the average stood at $2.9 million.
  • In the last 5 years, Arrowhead Pharmaceuticals' Change in Cash tumbled by 243435.28% in 2021 and then soared by 43571.43% in 2024.
  • Arrowhead Pharmaceuticals' Change in Cash (Quarter) stood at -$92.8 million in 2021, then soared by 201.68% to $94.4 million in 2022, then plummeted by 155.88% to -$52.7 million in 2023, then increased by 7.6% to -$48.7 million in 2024, then surged by 48.67% to -$25.0 million in 2025.
  • Its Change in Cash was -$25.0 million in Q4 2025, compared to $96.8 million in Q3 2025 and -$56.0 million in Q2 2025.